2006 Drug Development Vaccines 
PharmaTech
JUNE 23, 2025
Drug Enforcement Administration. USDOJ.gov , May 2006 (accessed April 29, 2025). Recent Videos Related Content Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics Cheryl Barton June 24th 2025 Article mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.
pharmaphorum
SEPTEMBER 18, 2020
However, it withdrew its neuropharmacological drug, Zelmid, which was an SSRI, due to concerns over side effects only a year after it was introduced in 1982. In 1990, the US Food and Drug Administration (FDA) requested Astra to change Losec’s brand name to Prilosec, to avoid confusion with Sanofi-Aventis’ diuretic, Lasix (furosemide).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
FEBRUARY 21, 2023
The company is developing PPMX-T002, an anti-cancer drug with an antibody targeting CDH3 connected with a radioisotope yttrium 90 (90Y). Perseus has been discussing the collaborative development of PPMX-T002 with various RI medical drug-developing companies, including PeptiDream and its subsidiary PDRAdhiopharma.
Putting Patients First Blog
APRIL 30, 2024
Assessment of length and readability of informed consent documents for COVID-19 vaccine trials. A blueprint for developing patient-centered core impact sets (PC-CIS). Re: Patient-Focused Drug Development: Guidance 1 – Collecting Comprehensive and Representative Input; Public Workshop (Docket No. Sincerely, Randall L.
Pharmaceutical Technology
JULY 23, 2008
Despite the enormous growth being enjoyed by the global oncology market, potential cancer cures are left on laboratory shelves on a regular basis, according to Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office. “You can get vaccines now to prevent cervical cancer.
Safe Biologics
SEPTEMBER 11, 2023
As we intended, this approach has been incredibly successful in controlling costs: the Congressional Budget Office projected drug spending between 2004-2013 to be $770 billion; actual expenses were 45% lower- at $421 billion. 3] “ Democrat plan on drug costs will stifle innovation”, San Antonio Express-News, May 12, 2021 [1] [link]
Pharmaceutical Technology
AUGUST 26, 2008
.” By the early 2000s AstraZeneca had already realised the critical importance of biotechnology, making a number of strategic investments in biotech companies, Abgenix in 2003, Cambridge Antibody Technology in 2006 and culminating in its acquisition of US biotech firm, Medimmune in April 2007 for £15bn.
Expert insights. Personalized for you.
52 
Let's personalize your content